☰

Prostate Cancer Clinical Trials

Last reviewed: November 14, 2026

Start with your disease setting, scans, testosterone status and prior treatment. A rising PSA does not by itself tell you whether a study requires local recurrence, distant metastases or castration-resistant disease. BRCA/HRR, PTEN and PSMA tests can matter, but their requirements differ by study.

Answer a few questions to find clinical trials matched to your specific Prostate Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →

Current Clinical Trial Landscape

Registry snapshot, November 14, 2026: a worldwide ClinicalTrials.gov query for Prostate Cancer, interventional studies, overall status Recruiting, returned 937 records. This is a broad search result, not 937 suitable options for one person. Site and cohort availability vary. Open the filtered registry search.

Selected research areas:

Approved treatment and trial eligibility are separate questions. U.S. biomarker-selected options in hormone-sensitive/metastatic androgen pathway modulation-naïve or -sensitive disease include capivasertib with abiraterone and prednisone for PTEN-deficient disease, talazoparib with enzalutamide for HRR-mutated disease, and niraparib/abiraterone with prednisone for BRCA2-mutated mCSPC. These tests and indications are not interchangeable. Pluvicto plus an ARPI also received a PSMA-positive hormone-sensitive indication in July 2026. Other mCRPC uses have their own prior-treatment restrictions; see the Pluvicto guide and PARP guide. Discuss local labels and standard-care alternatives with your oncologist.

→ For a focused, deeper view of the castration-resistant setting — PSMA radioligands, PARP/HRR combinations, next-gen AR agents, and PSMA/PSCA/STEAP1 cell therapies, with the Pluvicto evidence and biomarker guidance — see the dedicated metastatic castration-resistant prostate cancer (mCRPC) trials page.

Selected Trials by Disease Setting

All 37 cited registry records were checked November 14, 2026: 33 recruiting, three not yet recruiting, and one active but not recruiting. Studies not open to new enrollment are separated below. These are selected examples; overall recruitment does not guarantee an open site, cohort or personal eligibility.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ADT + AR-pathway inhibitor ± docetaxel is standard; 2026 added Pluvicto + ARPI for PSMA-positive disease (PSMAddition) and capivasertib + abiraterone for PTEN-deficient disease (CAPItello-281). Trials explore intensification and PSMA-based approaches:

Primary-Tumor Treatment in Metastatic Disease

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The most active research area in 2026. Phase 3 trials span bispecifics, PSMA radioligands (now including alpha-emitter 225Ac), AR-pathway intensification, and new ADCs:

CRPC With Limited Metastases on Functional Imaging

BRCA / HRR-Mutated Prostate Cancer

For men with germline or somatic BRCA1/2 or other HRR-pathway mutations. Olaparib + abiraterone is already approved first-line in BRCA-mutated mCRPC; trials below extend PARP and platinum strategies earlier in the disease course:

Biochemical Recurrence / Oligometastatic

Localized / Regional / Post-Surgery

Investigational PARP Strategy After Primary Radiation

Studies Not Open to New Enrollment

Not yet recruiting is different from an open study. Active, not recruiting means follow-up or treatment may continue without new enrollment; confirm changes with the study team.

Novel Approaches

Frequently Asked Questions

How do I find prostate cancer clinical trials?

Start with disease setting, recent scans, PSA and testosterone results, prior surgery/radiation and the exact AR-pathway drugs, chemotherapy or radioligand therapy you have received. Add BRCA/HRR, PTEN and PSMA results you know. ClinTrialFinder suggests studies for discussion; a study team confirms eligibility and availability.

How many prostate cancer trials are recruiting?

The November 14, 2026 worldwide ClinicalTrials.gov query for Prostate Cancer, interventional studies and Recruiting status returned 937 records. This broad registry result is not the number suitable for one person. The selected studies here have separately checked recruitment labels.

Which trials are for hormone-sensitive versus castration-resistant disease?

mHSPC/mCSPC studies and mCRPC studies address different settings. mCRPC requires progression despite castrate testosterone; prior AR-pathway, taxane and PSMA-radioligand exposure can further define a cohort. Do not substitute a trial from the other setting based only on a metastatic prostate cancer diagnosis.

Are there trials for rising PSA after prostate surgery or radiation?

Yes, selected recurrence studies include PSMA-directed salvage approaches (NCT04794777), PET-guided apalutamide/radiation after surgery (NCT04423211), and PROSTATE-IQ (NCT06274047). Imaging, prior local treatment, PSA level and treatment timing matter. A rising PSA alone does not establish distant metastatic or castration-resistant disease.

Do all BRCA, HRR, PTEN or PSMA findings open the same trials?

No. Those are different biomarkers and selection tests. EvoPAR-Prostate02 (NCT06952803), for example, requires centrally confirmed BRCA1/2 mutation plus a defined disease setting. A PSMA radioligand trial may require protocol-specific PET findings and prior treatment. Check the exact test and cohort rather than assuming a broad positive result is enough.

Drug target source: NCI identifies ifinatamab deruxtecan as a B7-H3/CD276 ADC. Study settings and recruitment were checked against the linked registry records.

Find Prostate Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific stage, biomarkers, and treatment history.

Find Matching Trials